Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.51 |
| ▸ | F3 | P13726 | 1/20 | 0.51 |
| ▸ | PRKAB2 | O43741 | 8/20 | 0.51 |
| ▸ | PRKAG1 | P54619 | 8/20 | 0.51 |
| ▸ | PRKAA2 | P54646 | 8/20 | 0.51 |
| ▸ | PRKAA1 | Q13131 | 8/20 | 0.51 |
| ▸ | PRKAG3 | Q9UGI9 | 8/20 | 0.51 |
| ▸ | PRKAG2 | Q9UGJ0 | 8/20 | 0.51 |
| ▸ | PRKAB1 | Q9Y478 | 8/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | MDH2 | P40926 | 2/20 | 0.46 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.45 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2965244 | 0.84 | F7 (0.66) | F7F3ALDH1A1HPGDCYP1A2 | |
| SCHEMBL30906941 | 0.84 | F7 (0.66) | F7F3ALDH1A1HPGDCYP1A2 | |
| SCHEMBL4336128 | 0.79 | DNA2 (0.46) | F7F3PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL10835850 | 0.76 | ALDH1A1 (0.59) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL398364 | 0.76 | F7 (0.81) | F7F3ALDH1A1HPGDCYP1A2 | |
| SCHEMBL2403560 | 0.75 | CA1 (0.76) | ALDH1A1HPGDMEN1KMT2ACA1 | |
| SCHEMBL30392504 | 0.75 | F7 (0.74) | F7F3PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL613332 | 0.75 | F7 (0.74) | F7F3PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL2406306 | 0.74 | CA1 (0.62) | ALDH1A1HPGDMEN1KMT2ACA1 | |
| SCHEMBL11014688 | 0.74 | PRKAB2 (0.57) | F7F3PRKAB2PRKAG1PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130078213-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC | 2013-03-28 | — | — | US | disclosed |
| CN-101343251-B | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP | 2011-11-09 | — | — | CN | disclosed |
| CN-101343250-B | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP | 2011-09-21 | — | — | CN | disclosed |
| EP-1889838-B1 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP (US) | 2009-10-14 | — | — | EP | disclosed |
| CN-101343251-A | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP (US) | 2009-01-14 | — | — | CN | disclosed |
| CN-101342169-A | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP (US) | 2009-01-14 | — | — | CN | disclosed |
| CN-101343250-A | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP (US) | 2009-01-14 | — | — | CN | disclosed |
| CN-100423721-C | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP (US) | 2008-10-08 | — | — | CN | disclosed |
| EP-1889838-A1 | Thrombopoietin mimetics | SmithKline Beecham Corporation (US) | 2008-02-20 | — | — | EP | disclosed |
| EP-1864981-A1 | Thrombopoietin mimetics | SmithKline Beecham Corporation (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070129338-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION | 2007-06-07 | — | — | US | disclosed |
| US-20040019190-A1 | Thrombopoietin mimetics | NOVARTIS AG (CH) | 2004-01-29 | — | — | US | disclosed |
| EP-1294378-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1294378-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001089457-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129338-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | F7 1439/4885F3 136/4885PRKAB2 1925/4885 |
| US-20130078213-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | F7 1439/4885F3 136/4885PRKAB2 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.